

Tozinameran

S

Various toxicities: 8 case reports

In an open-source online software LimeSurvey of 512 resident physicians conducted between 11 January and 16 March 2021 at Germany, 8 physicians (2 men and 6 women) aged 25-31 years were described, who developed vertigo, paresthesia, nervousness, confusion, visual hallucinations and sensory hypersensitivity following COVID-19 vaccination with tozinameran [*dosages not stated*].

The patients received two doses of COVID-19 vaccination with IM injection tozinameran [BNT162b2; Pfizer/BioNTech] 0.3mL. Following the first dose, two patients developed vertigo (1 patient) and paresthesia in the left thigh (1 patient) after 24 hours and 4 days, respectively. After the second dose, in between 24 to 48 hours, six patients of them developed bilateral paresthesia of the arms and hands (1 patient), vertigo (2 patients), nervousness and confusion (1 patient), visual hallucinations along with fever (1 patient) and sensory hypersensitivity (1 patient) [*outcomes not stated*].

Rahmani A, et al. Reactogenicity of bnt162b2 mrna covid-19 vaccine in a young working age population: A survey among medical school residents, within a mass vaccination campaign, in a regional reference teaching hospital in italy. *Vaccines* 9: No. 11, Nov 2021. Available from: URL: <https://www.mdpi.com/2076-393X/9/11/1269/pdf>

803619391